NEW YORK (GenomeWeb News) – ImaginAb, a Los Angeles-based developer of molecular imaging agents, has entered into an alliance with MacroGenics to develop companion imaging agents for an anti-cancer drug being developed by the Rockville, Md.-based biotech firm.
Under the deal announced today, ImaginAb will develop companion imaging agents for B7-H3, an immune regulator target for which MacroGenics is developing therapeutics. It also is developing a clinical imaging strategy based on a Macrogenics anti-CD3 antibody as a patient selection tool for ongoing clinical programs.
"Collaborating with MacroGenics provides the opportunity to demonstrate the ways in which ImaginAb's antibody fragment-based imaging technology can be used at the clinical nexus between cancer and immunology," ImaginAb CEO Christian Behrenbruch said in a statement.
The firms said that MacroGenics may receive future milestone payments and royalties associated with the anti-CD3 imaging product. Financial and additional terms were not disclosed.